A Phase 1 interventional study of Ibuprofen Tablets in Chronic Pain, sponsored by Overseas Pharmaceuticals, Ltd.. Completed at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-15.
Sponsored by Overseas Pharmaceuticals, Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Chronic Pain with a site in China — 14 open to participants now, 15 under way, 1 of them phase 3. Chronic Pain · China.
Among the 43 studies in Chronic Pain with a site in China, this one is the 29th largest by enrollment of the 34 interventional ones that give a count, is one of 2 that started in 2020, is one of 8 in phase 1, and was the 20th registered.
3,228 studies on the registry are indexed under Chronic Pain; 729 are open to participants now.
Browse Chronic Pain studies →14 of the 43 studies in Chronic Pain with a site in China are open now. Recruiting first, the newest first:
Shanghai Mental Health Center · Sites in China
Ages 18–80
Qilu Hospital of Shandong University · Sites in China
Ages 18–80
Beijing Tiantan Hospital · Sites in China
Ages 18–64
Xuanwu Hospital, Beijing · Sites in China
Ages 50–90
The Second Affiliated Hospital of Chongqing Medical University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 60 across 2,388 interventional studies indexed under Chronic Pain.
Median enrollment 80 across the 34 interventional studies, 300 across the 9 observational. Of the 19 that completed or were terminated, 4 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 43 have an industry lead sponsor. The 10 most frequent:
Overseas Pharmaceuticals, Ltd. is the lead sponsor of 12 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Overseas Pharmaceuticals, Ltd. has 1 study filed under Chronic Pain — fewer than ten, so there is no comparison to draw.
2 of the studies in Chronic Pain with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07323914Phase 3Xuanwu Hospital, BeijingClinical Analgesic Management in Dementia | 2027-01-01 |
| NCT06897007Beijing Tiantan HospitalChanges in Ciprofol Dosage in Patients With Insomnia Undergoing Intravenous Anesthesia | 2027-03-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 43 studies in Chronic Pain with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
An open-label, randomized, 3-way crossover study to evaluate the pharmacokinetics of investigational product "Ibuprofen Modified-Release Tablets 800 mg" in comparison to the reference standard "Ibuprofen Regular-Release Tablets 600 mg/800 mg" in normal healthy volunteers
Primary objective:
To evaluate the food effect of IBUMR and its bioavailability of single and multiple doses compared with reference drugs in normal healthy volunteers.
Secondary objectives:
This study consists of 3 treatment periods as below. For Treatment A and Treatment B, single- and multiple-dose stages are included.
Treatment A:
One tablet of IBUMR will be administered to the subjects under fasted condition, followed by a minimum of 72-hour washout interval. After the washout period, subjects will receive 1 × IBUMR every 12 hours for a total of 8 doses.
Treatment B:
One tablet of IBURed-800mg will be administered to the subjects under fasted condition, followed by a minimum of 72-hour washout interval. After the washout period, subjects will receive 1 × IBURed-600mg every 8 hours for a total of 12 doses.
Treatment C:
Single dose of IBUMR will be given to the subjects under fed condition (a standard high-fat, high calorie breakfast should be consumed within 30 minutes prior to dosing).
A minimum of 3-day washout interval will be introduced across the 3 treatment periods. Subjects will be required to be fasted for at least 10 hours prior to the administration of morning doses.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
BMI = Body Weight (kg) / [Height (m)]2 And body weight is not less than 50 kg and 45 kg for males and females, respectively.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Receive the investigational product and active comparator in a sequence of treatment A, treatment B and treatment C.
Drug: Ibuprofen Tablets
Receive the investigational product and active comparator in a sequence of treatment A, treatment C and treatment B.
Drug: Ibuprofen Tablets
Receive the investigational product and active comparator in a sequence of treatment B, treatment A and treatment C.
Drug: Ibuprofen Tablets
Receive the investigational product and active comparator in a sequence of treatment B, treatment C and treatment A.
Drug: Ibuprofen Tablets
Receive the investigational product and active comparator in a sequence of treatment C, treatment A and treatment B.
Drug: Ibuprofen Tablets
Receive the investigational product and active comparator in a sequence of treatment C, treatment B and treatment A.
Drug: Ibuprofen Tablets
Treatment A: One tablet of IBUMR will be administered to the subjects under fasted condition, followed by a minimum of 72-hour washout interval. After the washout period, subjects will receive 1 × IBUMR every 12 hours for a total of 7 doses. Treatment B: One tablet of IBURed will be administered to the subjects under fasted condition, followed by a minimum of 72-hour washout interval. After the washout period, subjects will receive 1 × IBURed every 8 hours for a total of 10 doses. Treatment C: Single dose of IBUMR will be given to the subjects under fed condition (a standard high-fat, high calorie breakfast should be consumed within 30 minutes prior to dosing).
Comparison of single-dose and multiple-dose bioavailability between IBUMR and IBURed
Comparison of single-dose and multiple-dose bioavailability between IBUMR and IBURed in log-transformed values of area under the curve from time 0 to the last measurable concentration (AUCL)
Time frame: After collecting blood samples from the last participant, up to 30 days
Comparison of single-dose and multi-dose bioavailability of IBUMR and IBURed
Comparison of single-dose and multiple-dose bioavailability between IBUMR and IBURed in log-transformed values of the peak concentration (Cmax)
Time frame: After collecting blood samples from the last participant, up to 30 days
Comparison of single - and multi-dose bioavailability of IBUMR and IBURed
Comparison of single-dose and multiple-dose bioavailability between IBUMR and IBURed in log-transformed values of area under the curve from time 0 to infinity (AUCinf).
Time frame: After collecting blood samples from the last participant, up to 30 days
To assess the food effect of IBUMR in the PK parameters
To assess the food effect of IBUMR in the PK parameters including Cmax
Time frame: After collecting blood samples from the last participant, up to 30 days
To evaluate the food effect of IBUMR on PK parameters
To assess the food effect of IBUMR in the PK parameters including time to reach peak concentration (Tmax)
Time frame: After collecting blood samples from the last participant, up to 30 days
To evaluate the food effects of IBUMR on PK parameters
To assess the food effect of IBUMR in the PK parameters including AUCL
Time frame: After collecting blood samples from the last participant, up to 30 days
Evaluate the food effect of IBUMR in PK parameters
To assess the food effect of IBUMR in the PK parameters including AUCinf
Time frame: After collecting blood samples from the last participant, up to 30 days
Determine the food effect of IBUMR in PK parameters
To assess the food effect of IBUMR in the PK parameters including elimination half-life (t1/2)
Time frame: After collecting blood samples from the last participant, up to 30 days
Single-dose PK measures
\-- Time to reach peak concentration (Tmax)
Time frame: After collecting blood samples from the last participant, up to 30 days
Single dose PK method
\-- Area under the concentration-time curve within time span t1 to t2 (AUCt1→t2)
Time frame: After collecting blood samples from the last participant, up to 30 days
Single dose PK
\-- Area under the concentration-time curve extrapolated from the last detectable sampling time point to infinity as a percentage of total AUC (AUCextrap)
Time frame: After collecting blood samples from the last participant, up to 30 days
Single dose PK step
\-- Elimination half-life (t1/2)
Time frame: After collecting blood samples from the last participant, up to 30 days
Single dose PK design
\-- Apparent oral clearance (CL/F)
Time frame: After collecting blood samples from the last participant, up to 30 days
Single dose PK moves
\-- Apparent volume of distribution after oral administration (Vd/F)
Time frame: After collecting blood samples from the last participant, up to 30 days
Multiple-dose PK measures
\-- Peak concentration at steady state (Cmax,ss)
Time frame: After collecting blood samples from the last participant, up to 30 days
Multiple - dosed PK
\-- Plasma drug concentration at a specified time t steady state (Ct,ss)
Time frame: After collecting blood samples from the last participant, up to 30 days
Multiple - dosed PK method
\-- Average concentration at steady state (Cavg)
Time frame: After collecting blood samples from the last participant, up to 30 days
Multiple - dosed PK steps
\-- Trough plasma concentration at steady state (Ctrough)
Time frame: After collecting blood samples from the last participant, up to 30 days
Multiple - dosed PK design
\-- Time to reach peak concentration at steady state (Tmax,ss)
Time frame: After collecting blood samples from the last participant, up to 30 days
Multiple - dosed PK plan
\-- Area under the concentration-time curve within time span t1 to t2 at steady state (AUCt1→t2,ss)
Time frame: After collecting blood samples from the last participant, up to 30 days
Multiple - dosed PK program
\-- AUC in 1 dosing interval (AUCτ) at steady state
Time frame: After collecting blood samples from the last participant, up to 30 days
Multiple - dosed PK process
\-- Terminal half-life at steady state (t1/2,ss)
Time frame: After collecting blood samples from the last participant, up to 30 days
Multiple - dosed PK arrangement
\-- Apparent oral clearance at steady state (CL/Fss)
Time frame: After collecting blood samples from the last participant, up to 30 days
Multiple - dosed PK planning
\-- Apparent volume of distribution after oral administration at steady state (Vd/Fss)
Time frame: After collecting blood samples from the last participant, up to 30 days
Assessment of effect duration for IBUMR
\-- For the plasma ibuprofen concentration of IBUMR at steady state, the time to drop to the Ctrough of IBURed-600mg will be calculated.
Time frame: After collecting blood samples from the last participant, up to 30 days
Evaluation of duration of IBUMR effect
\-- Percentage of the test drug-treated subjects with higher or equal plasma ibuprofen concentrations at 12-hour at steady state (C12,ss) compared to the Ctrough of IBURed-600mg will be calculated.
Time frame: After collecting blood samples from the last participant, up to 30 days
Incidence of treatment-emergent adverse events (safety and tolerability)
Incidence of AEs and SAEs
Time frame: After collecting blood samples from the last participant, up to 60 days
safety and tolerability
incidence of abnormal Physical examination
Time frame: After collecting blood samples from the last participant, up to 60 days
Incidence of treatment-emergent adverse events
abnormal Vital signs
Time frame: After collecting blood samples from the last participant, up to 60 days
Incidence of sudden adverse events (safety and tolerability)
abnormal laboratory tests results
Time frame: After collecting blood samples from the last participant, up to 60 days
Incidence of treatment-induced adverse events (safety and tolerability)
abnormal 12-lead ECG exams
Time frame: After collecting blood samples from the last participant, up to 60 days
Plan to share: No
Ran from Dec 2020 to primary completion in Feb 2021, 1 month.
Of 27 industry-sponsored phase 1 interventional studies under Chronic Pain, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 1 month is below that.
Counting every sponsor, half of 60 studies reached it within 12 months; a quarter within 6 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ibuprofen
Overseas Pharmaceuticals, Ltd.